文献速递免疫规划传染病防控与疫情报告

重组卡介苗与SARS-CoV-2蛋白联合接种可诱导强效抗病毒免疫

Co-administration of recombinant BCG and SARS-CoV-2 proteins leads to robust antiviral immunity.
PubMed 文献 · Vaccine · 2024-08-22

本研究在BALB/c小鼠中评估重组卡介苗(rBCG-N-SARS-CoV-2)与重组SARS-CoV-2蛋白(N、S或RBD-Omicron)加铝佐剂联合接种、并以重组蛋白加强的免疫策略。结果显示该方案安全性良好,可激活针对N、S和RBD抗原的CD4+和CD8+ T细胞并分泌抗病毒型细胞因子,同时诱导针对N、S和RBD的高滴度特异性抗体及SARS-CoV-2中和抗体。作者认为该联合疫苗可能是控制特定SARS-CoV-2变异株的有效替代方案,尤其适用于新生儿。

要点

  • rBCG-N-SARS-CoV-2与重组SARS-CoV-2蛋白联合接种在小鼠中安全性良好。
  • 该策略激活针对N、S和RBD抗原的CD4+和CD8+ T细胞并诱导抗病毒型细胞因子分泌。
  • 该策略诱导针对N、S和RBD的高滴度特异性抗体及SARS-CoV-2中和抗体。

核心结论

  • rBCG-N-SARS-CoV-2与重组SARS-CoV-2蛋白联合接种可能是控制特定SARS-CoV-2变异株的有效替代方案。
  • 作者认为该联合疫苗因安全性和诱导病毒特异性免疫应答的能力,可能是预防该病毒的有吸引力的候选疫苗,尤其适用于新生儿。

研究设计与样本

  • BALB/c小鼠经rBCG-N-SARS-CoV-2与铝佐剂中的重组SARS-CoV-2蛋白免疫,随后以重组蛋白加强,评估安全性和针对SARS-CoV-2抗原的病毒特异性细胞与体液免疫应答。

主要发现

  • 以rBCG-N-SARS-CoV-2加重组蛋白免疫安全性良好。
  • 免疫后激活了识别SARS-CoV-2 N、S和RBD抗原的CD4+和CD8+ T细胞,这些细胞能够分泌具有抗病毒特征的细胞因子。
  • 该免疫策略诱导了针对N、S和RBD的高滴度特异性抗体以及SARS-CoV-2中和抗体。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: SARS-CoV-2 is the causative virus of COVID-19, which has been responsible for millions of deaths worldwide since its discovery. After its emergence, several variants have been identified that challenge the efficacy of the available vaccines. Previously, we generated and evaluated a vaccine based on a recombinant Bacillus Calmette-Guérin (rBCG) expressing the nucleoprotein (N) of SARS-CoV-2 (rBCG-N-SARS-CoV-2). This protein is a highly immunogenic antigen and well conserved among variants. Here, we tested the administration of this vaccine with recombinant N and viral Spike proteins (S), or Receptor Binding Domain (RBD-Omicron variant), plus a booster with the recombinant proteins only, as a novel and effective strategy to protect against SARS-CoV-2 variants. METHODS: BALB/c mice were immunized with rBCG-N-SARS-CoV-2 and recombinant SARS-CoV-2 proteins in Alum adjuvant, followed by a booster with recombinant proteins to assess the safety and virus-specific cellular and humoral immune responses against SARS-CoV-2 antigens. RESULTS: Immunization with rBCG-N-SARS-CoV-2 + recombinant proteins as a vaccine was safe and promoted the activation of CD4+ and CD8+ T cells that recognize SARS-CoV-2 N, S, and RBD antigens. These cells were able to secrete cytokines with an antiviral profile. This immunization strategy also induced robust titers of specific antibodies against N, S, and RBD and neutralizing antibodies of SARS-CoV-2. CONCLUSIONS: Co-administration of the rBCG-N-SARS-CoV-2 vaccine with recombinant SARS-CoV-2 proteins could be an effective alternative to control particular SARS-CoV-2 variants. Due to its safety and capacity to induce virus-specific immune responses, we believe the rBCG-N-SARS-CoV-2 + Proteins vaccine could be an attractive candidate to protect against this virus, especially in newborns.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ramírez MA, Loaiza RA, Martínez-Balboa Y, et al. Co-administration of recombinant BCG and SARS-CoV-2 proteins leads to robust antiviral immunity. Vaccine. 2024. PMID: 39178767. doi:10.1016/j.vaccine.2024.126203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。